Icodextrin Fulfills Unmet Clinical Need of PD Patients

Improved Ultrafiltration

Richard J. Hamburger, Michael Kraus

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Extraneal®, a new peritoneal dialysis solution, was recently approved by the U.S. Food and Drug Administration (FDA) for use during the long dwell of peritoneal dialysis (PD). It represents a new class of osmotic agents with demonstrated clinical advantages over standard dextrose-based solutions, particularly for patients who would benefit from an improvement in ultrafiltration (UF). Studies comparing icodextrin and 2.5% dextrose for the long dwell have consistently demonstrated greater UF with icodextrin. In addition, because the icodextrin solution does not contain dextrose, the daily glucose load and associated risk of metabolic abnormalities are reduced. Icodextrin also has benefits beyond improved UF, including improvement in blood pressure control, fluid balance, and glycemic control, as well as extension of the time patients are able to stay on the therapy. These benefits could allow patients the opportunity to continue on their preferred dialysis modality.

Original languageEnglish
Pages (from-to)675-684
Number of pages10
JournalDialysis and Transplantation
Volume32
Issue number11
StatePublished - Nov 2003

Fingerprint

Ultrafiltration
Peritoneal Dialysis
Glucose
Water-Electrolyte Balance
Dialysis Solutions
United States Food and Drug Administration
Dialysis
icodextrin
Blood Pressure

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

Icodextrin Fulfills Unmet Clinical Need of PD Patients : Improved Ultrafiltration. / Hamburger, Richard J.; Kraus, Michael.

In: Dialysis and Transplantation, Vol. 32, No. 11, 11.2003, p. 675-684.

Research output: Contribution to journalArticle

Hamburger, Richard J. ; Kraus, Michael. / Icodextrin Fulfills Unmet Clinical Need of PD Patients : Improved Ultrafiltration. In: Dialysis and Transplantation. 2003 ; Vol. 32, No. 11. pp. 675-684.
@article{024eed64edba4359b78c290053b27cf3,
title = "Icodextrin Fulfills Unmet Clinical Need of PD Patients: Improved Ultrafiltration",
abstract = "Extraneal{\circledR}, a new peritoneal dialysis solution, was recently approved by the U.S. Food and Drug Administration (FDA) for use during the long dwell of peritoneal dialysis (PD). It represents a new class of osmotic agents with demonstrated clinical advantages over standard dextrose-based solutions, particularly for patients who would benefit from an improvement in ultrafiltration (UF). Studies comparing icodextrin and 2.5{\%} dextrose for the long dwell have consistently demonstrated greater UF with icodextrin. In addition, because the icodextrin solution does not contain dextrose, the daily glucose load and associated risk of metabolic abnormalities are reduced. Icodextrin also has benefits beyond improved UF, including improvement in blood pressure control, fluid balance, and glycemic control, as well as extension of the time patients are able to stay on the therapy. These benefits could allow patients the opportunity to continue on their preferred dialysis modality.",
author = "Hamburger, {Richard J.} and Michael Kraus",
year = "2003",
month = "11",
language = "English",
volume = "32",
pages = "675--684",
journal = "Dialysis and Transplantation",
issn = "0090-2934",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Icodextrin Fulfills Unmet Clinical Need of PD Patients

T2 - Improved Ultrafiltration

AU - Hamburger, Richard J.

AU - Kraus, Michael

PY - 2003/11

Y1 - 2003/11

N2 - Extraneal®, a new peritoneal dialysis solution, was recently approved by the U.S. Food and Drug Administration (FDA) for use during the long dwell of peritoneal dialysis (PD). It represents a new class of osmotic agents with demonstrated clinical advantages over standard dextrose-based solutions, particularly for patients who would benefit from an improvement in ultrafiltration (UF). Studies comparing icodextrin and 2.5% dextrose for the long dwell have consistently demonstrated greater UF with icodextrin. In addition, because the icodextrin solution does not contain dextrose, the daily glucose load and associated risk of metabolic abnormalities are reduced. Icodextrin also has benefits beyond improved UF, including improvement in blood pressure control, fluid balance, and glycemic control, as well as extension of the time patients are able to stay on the therapy. These benefits could allow patients the opportunity to continue on their preferred dialysis modality.

AB - Extraneal®, a new peritoneal dialysis solution, was recently approved by the U.S. Food and Drug Administration (FDA) for use during the long dwell of peritoneal dialysis (PD). It represents a new class of osmotic agents with demonstrated clinical advantages over standard dextrose-based solutions, particularly for patients who would benefit from an improvement in ultrafiltration (UF). Studies comparing icodextrin and 2.5% dextrose for the long dwell have consistently demonstrated greater UF with icodextrin. In addition, because the icodextrin solution does not contain dextrose, the daily glucose load and associated risk of metabolic abnormalities are reduced. Icodextrin also has benefits beyond improved UF, including improvement in blood pressure control, fluid balance, and glycemic control, as well as extension of the time patients are able to stay on the therapy. These benefits could allow patients the opportunity to continue on their preferred dialysis modality.

UR - http://www.scopus.com/inward/record.url?scp=0242710164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242710164&partnerID=8YFLogxK

M3 - Article

VL - 32

SP - 675

EP - 684

JO - Dialysis and Transplantation

JF - Dialysis and Transplantation

SN - 0090-2934

IS - 11

ER -